Suppr超能文献

人黑色素瘤发生发展过程中细胞间黏附分子1(ICAM-1)的组织病理学表达分析

Histopathological expression analysis of intercellular adhesion molecule 1 (ICAM-1) along development and progression of human melanoma.

作者信息

Galore-Haskel Gilli, Baruch Erez N, Berg Amy L, Barshack Iris, Zilinsky Itzhak, Avivi Camila, Besser Michal J, Schachter Jacob, Markel Gal

机构信息

Ella Lemelbaum Institute of Immuno-Oncology, Ramat-Gan, Israel.

Clinical Microbiology and Immunology, Tel-Aviv, Israel.

出版信息

Oncotarget. 2017 Sep 14;8(59):99580-99586. doi: 10.18632/oncotarget.20884. eCollection 2017 Nov 21.

Abstract

Intercellular adhesion molecule 1 (ICAM-1) protein is an important adhesion molecule that facilitates metastasis on one hand, and on the other hand supports the immunological synapse necessary for T-cell mediated elimination. The expression pattern of ICAM-1 in melanoma was studied more than two decades ago, mainly in cell lines or in unmatched melanoma specimens. By using real time PCR we could not demonstrate a clear difference in ICAM-1 mRNA levels between primary melanocytes and primary cultures of metastatic melanoma. However, immunohistochemistry staining of progression tissue microarray comprised of samples of different disease stages derived from different patients, demonstrated a dramatic ICAM-1 upregulation particularly upon the transition from primary tumor to lymph node metastasis. There was no significant difference between lymph node and distant metastases. Importantly, these results were confirmed in an independent tissue microarray comprised of patient-paired specimens from progressive stages of the patient's disease. These data indicate that ICAM-1 upregulation is required to initiate the lymphatic spread of melanoma (Stage III) but no further increase is associated with progression to remote organs (Stage IV).

摘要

细胞间黏附分子1(ICAM-1)蛋白是一种重要的黏附分子,一方面促进转移,另一方面支持T细胞介导的清除所必需的免疫突触。二十多年前就对ICAM-1在黑色素瘤中的表达模式进行了研究,主要是在细胞系或不匹配的黑色素瘤标本中。通过实时PCR,我们未能证明原发性黑素细胞与转移性黑色素瘤原代培养物之间ICAM-1 mRNA水平存在明显差异。然而,对由来自不同患者的不同疾病阶段样本组成的进展性组织芯片进行免疫组织化学染色,结果显示ICAM-1显著上调,尤其是在从原发性肿瘤向淋巴结转移转变时。淋巴结转移和远处转移之间没有显著差异。重要的是,这些结果在由患者疾病进展阶段的患者配对标本组成的独立组织芯片中得到了证实。这些数据表明,ICAM-1上调是黑色素瘤发生淋巴转移(III期)所必需的,但向远处器官转移(IV期)时并没有进一步增加。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/826a/5725116/35d7fe6e5db5/oncotarget-08-99580-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验